Results 71 to 80 of about 45,189 (317)

The importance of early arthritis in patients with rheumatoid arthritis [PDF]

, 2018
Rheumatoid arthritis (RA) is a systemic inflammatory disorder that manifests predominantly in the synovial joint, where it causes a chronic inflammatory process, leading to early osteoarticular destructions.
Diaconu, Camelia C, Hainarosie, Razvan, Iancu, Mihaela A, Iftimie, Georgiana, Isvoranu, Gheorghita, Marcu, Dragos, Neagu, Tiberiu P, Pantea Stoian, Anca, Socea, Bogdan, Stanescu, Ana Maria Alexandra   +9 more
core   +3 more sources

Sex Differences in Medication Discontinuation in Axial Spondyloarthritis

Arthritis Care &Research, EarlyView.
Objective We examined sex differences in medication discontinuation among patients with axial spondyloarthritis (axSpA) initiating tumor necrosis factor inhibitors (TNFi), interleukin‐17 inhibitors (IL‐17i), or JAK inhibitors (JAKi). Methods Using data from the Rheumatology Informatics System for Effectiveness (RISE) Registry (2003–2025), we assessed ...
Rachael Stovall, Cinthia Blat, Eric Roberts, Jean W. Liew, Katherine Wysham, Namrata Singh, Janna Friedly, Lianne S. Gensler, Gabriela Schmajuk, Jinoos Yazdany   +9 more
wiley   +1 more source

Treating Rheumatoid Arthritis yesterday and today [PDF]

, 2004
Rheumatoid arthritis is a chronic, systemic inflammatory disorder that mainly affects joints. It is the most common form of inflammatory joint disease, and the second commonest joint disease, osteoarthritis being the commonest.
Mallia, Carmel
core  

Secukinumab versus adalimumab for psoriatic arthritis: comparative effectiveness up to 48 weeks using a matching-adjusted indirect comparison [PDF]

, 2018
Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor ...
Gandhi, Kunal, Hunger, Matthias, Jugl, Steffen M., Karabis, Andreas, McInnes, Iain B., Mease, Philip J., Mpofu, Shephard, Nash, Peter, Thom, Howard   +8 more
core   +2 more sources

Evaluation of a novel EHR sidecar application to display RA clinical outcomes during clinic visits: results of a stepped‐wedge cluster randomized pragmatic trial

Arthritis Care &Research, Accepted Article.
Objective We developed a novel EHR sidecar application to visualize key rheumatoid arthritis (RA) outcomes, including disease activity, physical function, and pain, via a patient‐facing graphical interface designed for use during outpatient visits (“RA PRO dashboard”).
Gabriela Schmajuk, Jing Li, Cathy Nasrallah, Cherish Wilson, Alicia Hamblin, Christine Hariz, Cammie Young, Stephen Shiboski, Emma Kersey, Mary Nakamura, Judith F. Ashouri, Mehrdad Matloubian, Andrew J. Gross, Jennifer Barton, Beth Berrean, Jonathan Prugh, Jinoos Yazdany   +16 more
wiley   +1 more source

Combination of Second-line Antirheumatic Drugs

Annals of Medicine, 1997
Single drug therapy is often not satisfactory in the treatment of chronic arthritis. The combination of second-line antirheumatic drugs is therefore increasingly employed. Various strategies of combining drugs can be used, starting with combinations or adding agents in case of insufficient effect of single therapy.
Haagsma, C.J., Riel, P.L.C.M. van
openaire   +4 more sources

Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System [PDF]

, 2016
Aim: Biological disease-modifying antirheumatic drugs (bDMARDs) are used to treat rheumatoid arthritis (RA) with adalimumab and etanercept the most used bDMARDs in Brazil.
Acurcio, Francisco De Assis, Almeida, Alessandra Maciel, Alvares, Juliana, Bennie, Marion, De Oliveira, Haliton Alves, Dos Santos, Jéssica Barreto Ribeiro, Godman, Brian, Guerra, Augusto Afonso, Kakehasi, Adriana Maria   +8 more
core   +1 more source

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drug

Arthritis Care &Research, EarlyView.
Objective We assessed the effectiveness of PrismRA to improve clinical outcomes among patients with rheumatoid arthritis (RA) initiating treatment with a biologic or targeted synthetic disease‐modifying antirheumatic drug (b/tsDMARD). Methods PrismRA incorporated 19 gene expression features and four clinical features to assess a patient's likelihood of
Fenglong Xie, Timothy Beukelman, Nicholas P. McCormick, Jeffrey R. Curtis   +3 more
wiley   +1 more source

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARD), targeted synthetic DMARD (tsDMARD) and biosimilar DMARD (bsDMARD) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity [PDF]

, 2023
Juthamas Prawjaeng, Pattara Leelahavarong, Nuttakarn Budtarad, Songyot Pilasant, Chonticha Chanjam, Wanruchada Katchamart, Pongthorn Narongroeknawin, Tasanee Kitumnuaypong   +7 more
openalex   +1 more source

Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia [PDF]

, 2004
We previously demonstrated prolonged, profound CD4+ T-lymphopenia in rheumatoid arthritis (RA) patients following lymphocyte-depleting therapy. Poor reconstitution could result either from reduced de novo T-cell production through the thymus or from poor
Bingham, S.J., Brown, A.K., Buch, M., Douglas, S.H., Emery, P., Fearon, U., Field, S.L., Isaacs, J.D., Lawson, C.A., Ma, D., Maltby, S.L., Markham, A.F., Masurel, A., McGonagle, D., Moore, J., Morgan, A.W., Papadaki, H.A., Patel, P., Ponchel, F., Protheroe, A., Quinn, M., Short, K., Snowden, J., Straszynski, L., van Laar, J.M., Veale, D.J., Verburg, R.J.   +26 more
core   +2 more sources